Satellos Bioscience Inc.
OTC: MSCLF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Francis Gleeson
- Employees
- 14
- Headquarters
- Toronto, Canada
- IPO year
- 2012
- Market cap
- $96.6M
- Website
- https://satellos.com
Loading MSCLF…
Loading profile data…Frequently asked questions about MSCLF
What does Satellos Bioscience Inc. (MSCLF) do?
Satellos Bioscience Inc., a company dedicated to regenerative medicine, focuses on pioneering treatments for various degenerative muscle conditions. A cornerstone of their research is a leading program aimed at developing an orally administered drug. This therapeutic seeks to rectify muscle stem cell polarity, which in turn is intended to restor...
Where does MSCLF trade?
Satellos Bioscience Inc. (MSCLF) trades on the Other OTC.
What sector is MSCLF in?
Satellos Bioscience Inc. (MSCLF) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Satellos Bioscience Inc.?
Francis Gleeson is the chief executive officer of Satellos Bioscience Inc. (MSCLF).
Where is Satellos Bioscience Inc. headquartered?
Satellos Bioscience Inc. is headquartered in Canada.
Does MSCLF pay a dividend?
Satellos Bioscience Inc. (MSCLF) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did MSCLF go public?
Satellos Bioscience Inc. (MSCLF) completed its initial public offering in 2012.